• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[膀胱癌患者尿酶活性的变化]

[Changes of urinary enzyme activity in cancer of the urinary bladder].

作者信息

Nizamova R S

出版信息

Vopr Onkol. 2006;52(4):455-7.

PMID:17024822
Abstract

Assays of blood serum and urine samples from patients with cancer of the urinary bladder established enhanced levels of lactate dehydrogenase (LDH). The findings were significant as far as malignancies were concerned. Male patients with transitional cell carcinoma revealed significant increase in DH blood serum while, in moderately- and low-differentiated tumor cases, it was higher in urine. In female patients, increased levels were registered in urine and in low-differentiated tumor only. Prognostic value of LDH levels in males was relatively higher.

摘要

对膀胱癌患者的血清和尿液样本进行的检测发现,乳酸脱氢酶(LDH)水平升高。就恶性肿瘤而言,这些发现具有重要意义。患有移行细胞癌的男性患者血清中的LDH显著增加,而在中低分化肿瘤病例中,尿液中的LDH水平更高。在女性患者中,仅在尿液和低分化肿瘤中检测到LDH水平升高。男性患者中LDH水平的预后价值相对较高。

相似文献

1
[Changes of urinary enzyme activity in cancer of the urinary bladder].[膀胱癌患者尿酶活性的变化]
Vopr Onkol. 2006;52(4):455-7.
2
Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder.尿液中可溶性E-钙黏蛋白水平在膀胱移行细胞癌检测中的应用
Eur Urol. 2005 Jul;48(1):69-76. doi: 10.1016/j.eururo.2005.02.012. Epub 2005 Mar 8.
3
Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer.肿瘤源性透明质酸酶:一种用于高级别膀胱癌的诊断性尿液标志物。
Cancer Res. 1997 Feb 15;57(4):778-83.
4
Urine prothymosin-alpha as novel tumor marker for detection and follow-up of bladder cancer.尿前胸腺素α作为膀胱癌检测及随访的新型肿瘤标志物。
Urology. 2006 Feb;67(2):294-9. doi: 10.1016/j.urology.2005.08.034.
5
Cellular fibronectin in patients with transitional cell carcinoma of the bladder.膀胱移行细胞癌患者的细胞纤连蛋白
Urol Res. 2003 Feb;30(6):363-6. doi: 10.1007/s00240-002-0280-3. Epub 2002 Oct 1.
6
Limitations in the use of glutathione S-transferase P1 in urine as a marker for bladder cancer.尿中谷胱甘肽S-转移酶P1作为膀胱癌标志物应用的局限性。
Anticancer Res. 1998 Sep-Oct;18(5B):3771-2.
7
Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma.膀胱镜活检和尿液细胞学检查中尿路上皮细胞和炎性细胞上的环氧化酶-2表达作为膀胱癌的一种可能预测标志物
APMIS. 2009 Jan;117(1):45-52. doi: 10.1111/j.1600-0463.2008.00014.x.
8
Diagnosis of bladder cancer by analysis of urinary fibronectin.通过分析尿纤连蛋白诊断膀胱癌
Urology. 2005 Feb;65(2):284-9. doi: 10.1016/j.urology.2004.09.028.
9
Considerations on the use of urine markers for bladder cancer.
Eur Urol. 2008 May;53(5):880-1. doi: 10.1016/j.eururo.2008.01.043. Epub 2008 Jan 22.
10
Studies on lactic dehydrogenase of patients with urinary bladder tumors. I. Urinary lactic dehydrogenase.
Invest Urol. 1979 Sep;17(2):120-4.